메뉴 건너뛰기




Volumn 129, Issue 13, 2014, Pages 1407-1414

National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation

Author keywords

anticoagulants; atrial flutter; blood coagulation; stroke

Indexed keywords

WARFARIN;

EID: 84897443099     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002601     Document Type: Article
Times cited : (125)

References (23)
  • 2
  • 5
    • 57149140461 scopus 로고    scopus 로고
    • Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    • ACTIVE W Investigators
    • Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
    • (2008) Circulation , vol.118 , pp. 2029-2037
    • Connolly, S.J.1    Pogue, J.2    Eikelboom, J.3    Flaker, G.4    Commerford, P.5    Franzosi, M.G.6    Healey, J.S.7    Yusuf, S.8
  • 6
    • 34447306023 scopus 로고    scopus 로고
    • Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action
    • Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414-1419.
    • (2007) Arch Intern Med , vol.167 , pp. 1414-1419
    • Wysowski, D.K.1    Nourjah, P.2    Swartz, L.3
  • 7
    • 33847006936 scopus 로고    scopus 로고
    • Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and v
    • White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239-245.
    • (2007) Arch Intern Med , vol.167 , pp. 239-245
    • White, H.D.1    Gruber, M.2    Feyzi, J.3    Kaatz, S.4    Tse, H.F.5    Husted, S.6    Albers, G.W.7
  • 8
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • American College of Chest Physicians
    • Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(suppl):160S-198S.
    • (2008) Chest , vol.133 , Issue.SUPPL.
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3    Jacobson, A.4    Crowther, M.5    Palareti, G.6
  • 9
    • 79958813704 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    • Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
    • (2011) Circulation , vol.123 , pp. 2562-2570
    • Shah, S.V.1    Gage, B.F.2
  • 11
    • 80155206426 scopus 로고    scopus 로고
    • Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: A consensus document of the Italian Federation of Thrombosis Centers (FCSA)
    • Italian Federation of Thrombosis Centers.
    • Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: a consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-876.
    • (2011) Thromb Haemost , vol.106 , pp. 868-876
    • Pengo, V.1    Crippa, L.2    Falanga, A.3    Finazzi, G.4    Marongiu, F.5    Palareti, G.6    Poli, D.7    Testa, S.8    Tiraferri, E.9    Tosetto, A.10    Tripodi, A.11    Manotti, C.12
  • 14
    • 78649342646 scopus 로고    scopus 로고
    • Patient characteristics associated with oral anticoagulation control: Results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
    • Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182-2191.
    • (2010) J Thromb Haemost , vol.8 , pp. 2182-2191
    • Rose, A.J.1    Hylek, E.M.2    Ozonoff, A.3    Ash, A.S.4    Reisman, J.I.5    Berlowitz, D.R.6
  • 18
    • 55749115770 scopus 로고    scopus 로고
    • Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: Potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF v
    • Hylek EM, Frison L, Henault LE, Cupples A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke. 2008;39:3009-3014.
    • (2008) Stroke , vol.39 , pp. 3009-3014
    • Hylek, E.M.1    Frison, L.2    Henault, L.E.3    Cupples, A.4
  • 19
    • 54049115489 scopus 로고    scopus 로고
    • Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation
    • Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39:2736-2743.
    • (2008) Stroke , vol.39 , pp. 2736-2743
    • Shen, A.Y.1    Yao, J.F.2    Brar, S.S.3    Jorgensen, M.B.4    Wang, X.5    Chen, W.6
  • 23
    • 84855402737 scopus 로고    scopus 로고
    • Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism
    • Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125:159-164.
    • (2012) Circulation , vol.125 , pp. 159-164
    • Granger, C.B.1    Armaganijan, L.V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.